+0.0104  (+1.97%)
Volume (24h): 8.07M Day Range: 0.5101 - 0.5450
Market Cap: 45.29M 52W Range: 0.1650 - 3.05
May-14-20 11:00AM Guardion Health Sciences Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
May-12-20 11:05AM Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment DensityGlobeNewswire
Apr-15-20 01:05PM Guardion Health Sciences to Present at the April 2020 Virtual Investor SummitGlobeNewswire
Apr-14-20 03:00PM Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant ComplexGlobeNewswire
Apr-01-20 11:00AM Guardion Health Sciences Receives Initial Order from Malaysian Company for Exclusive Immuno-Supportive FormulaGlobeNewswire
Mar-30-20 01:00PM Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and OverviewGlobeNewswire
Mar-19-20 04:05PM Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price RuleGlobeNewswire
Mar-06-20 01:05PM Guardion Health Sciences Receives $3.5 Million from Exercise of WarrantsGlobeNewswire
Feb-26-20 12:00PM Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive FormulaGlobeNewswire
Feb-06-20 12:00PM Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract InfectionsGlobeNewswire
Jan-07-20 04:02PM Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business LineGlobeNewswire
Nov-14-19 12:00PM Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019GlobeNewswire
Oct-30-19 04:33PM Guardion Health Sciences Closes $8.4 Million Underwritten Public OfferingGlobeNewswire
Oct-28-19 01:21PM Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public OfferingGlobeNewswire
Oct-23-19 11:00AM Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SFGlobeNewswire
Oct-17-19 02:40PM Here's Why We're A Bit Worried About Guardion Health Sciences's (NASDAQ:GHSI) Cash Burn SituationSimply Wall St.
Oct-10-19 02:30PM Guardion® Announces Statistically Significant Blood Assay Study ResultsGlobeNewswire
Sep-23-19 02:30PM Guardion Health Sciences Acquires the NutriGuard Brand of ProductsGlobeNewswire
Sep-03-19 11:00AM Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity TestGlobeNewswire
Aug-15-19 08:05PM Guardion Health Sciences Closes $5.8 Million Underwritten Public OfferingGlobeNewswire
12:35PM Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public OfferingGlobeNewswire
Aug-13-19 01:00PM Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public OfferingGlobeNewswire
Aug-12-19 12:40PM Guardion Health Sciences Reports June 30, 2019 Interim Results of OperationsGlobeNewswire
Aug-06-19 11:00AM Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical TrialGlobeNewswire
Jul-19-19 06:47PM What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)?Simply Wall St.
Jul-17-19 11:00AM Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents RegistryGlobeNewswire
Jun-20-19 11:00AM Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European UnionGlobeNewswire
Jun-04-19 11:00AM Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’GlobeNewswire
May-09-19 02:14PM Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2GlobeNewswire
May-07-19 11:00AM Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe GlaucomaGlobeNewswire
May-01-19 11:00AM Guardion Health Sciences, Inc. Receives Official Trademark Registrations in ChinaGlobeNewswire
Apr-17-19 01:01PM Results of Lumega-Z Data to be Presented at ARVOGlobeNewswire
Apr-09-19 04:20PM Guardion Health Sciences, Inc. Announces Closing of Initial Public OfferingGlobeNewswire
Guardion Health Sciences, Inc., a specialty health sciences company, develops, formulates, and distributes condition-specific medical foods in the United States and internationally. It operates in two segments, Medical Foods and Vision Testing Diagnostics. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; MapcatSF, a medical device that measures the macular pigment optical density; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Vision Testing Diagnostics segment develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. Its products include VectorVision CSV-1000, an instrument for contrast sensitivity testing; and ESV-3000 ETDRS, a device for early treatment diabetic retinopathy study in visual acuity testing. The company distributes its products through direct sales force, as well as through its Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)